A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
← catalyst calendarNCT07361289 · readout in 734 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
15
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-15 | actual | When the study began enrolling |
| Primary completion | 2028-08-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertrophic Cardiomyopathy
Intervention
- Drug: Mavacamten
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in Valsalva left ventricular outflow tract (LVOT) gradient
measured Week 48, Week 96
Change from baseline in resting valsalva left ventricular outflow tract (LVOT) gradient
measured Week 48, Week 96
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed